|
| Study | Population | Study type (data source) | AKI (WRF) definition | Incidence AKI (%) | Cardiac disease | Outcome |
|
| Nohria et al., 2008 [15] | n = 433
Mean Age 56 yrs
Male %
DM 34%
HTN 47% | Retrospective
(ESCAPE Trial) | SCr > 26.5 μmol/L | 29.5 | Hospitalized ADHF | All-cause death (6 m) (HR) increased for SCr > 106.1
AKI (>26.5 μmol/L) not associated with death/readmission |
| Logeart et al., 2008 [16] | n = 416
Age 71 yrs
Male 59%
DM 23%
HTN 42% | Prospective | SCr > 26.5 μmol/L | 37 | Hospitalized ADHF Prevalence:
LVEF 0.35
LVEF ≤ 0.45 70%
Prior HF 45%
Prior MI 55% | All-cause death (6 m) or Readmission (adj-HR) 1.74
Increased LOS 3 d
Risk persisted whether AKI transient or not |
| Metra et al., 2008 [17] | n = 318
Mean Age 68 yrs
Male 60%
DM 34%
HTN 53% | Prospective | SCr > 26.5 μmol/L & ≥ 25% | 34 | Hospitalized ADHF Prevalence:
Prior MI 51%
Prior HF 58% | CV death or readmission (adj-HR) 1.47
Increased LOS 7 d |
|
Aronson and Burger [18] | n = 467 | Prospective | SCr > 44.2 μmol/L | 33.9 Transient 7.9 Persistent 14.3 | Hospitalized ADHF | All-cause death (6 m) 17.3%, 20.5%, and 46.1% for no WRF, transient WRF, persistent WRF
Adj-HR for persistent WRF 3.2 (95% CI, 2,1–5.0) |
| Belziti et al., 2010 [19] | n = 200 | Retrospective | SCr > 26.5 μmol/L & ≥ 25% | 23 | Hospitalized ADHF | Higher mortality at 1-year (P < .01)
Rehospitalization for WRF (HR 1.65, P = .003)
Longer median LOS for WRF (9 versus 4 days, P < .05) |
| Kociol et al., 2010 [20] | n = 20,063 | Retrospective | SCr > 26.5 μmol/L | 17.8 | Hospitalized ADHF | 1-year mortality 35.4% (HR 1.12, 95% CI, 1.4–1.20)
Rehospitalization 64.5% |
|
